Biotech News
Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption
– Commercial adoption of Symvess® accelerated during the third quarter with sales totaling $1.0 million, a 151% increase over the 2 nd quarter. – Symvess commercial momentum continued into the fourth quarter, with October 2026 sales totaling $0.8 million.
